167 related articles for article (PubMed ID: 19687323)
1. Trastuzumab beyond disease progression: case closed?
Valabrega G; Aglietta M; Montemurro F
J Clin Oncol; 2009 Sep; 27(27):e121-2; author reply e124-5. PubMed ID: 19687323
[No Abstract] [Full Text] [Related]
2. Continuing trastuzumab beyond progression.
Jahanzeb M
J Clin Oncol; 2009 Apr; 27(12):1935-7. PubMed ID: 19289613
[No Abstract] [Full Text] [Related]
3. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
Ferretti G; Fabi A; Felici A; Papaldo P
J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
[No Abstract] [Full Text] [Related]
4. Continuation of trastuzumab beyond disease progression.
Montemurro F; Faggiuolo R; Redana S; Donadio M; Minischetti M; Durando A; Vietti-Ramus G; Buosi R; Aglietta M
J Clin Oncol; 2005 Apr; 23(12):2866-8; discussion 2868-9. PubMed ID: 15838006
[No Abstract] [Full Text] [Related]
5. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
6. Trastuzumab in the treatment of breast cancer.
Hortobagyi GN
N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
[No Abstract] [Full Text] [Related]
7. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
8. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y; Suzuki Y; Saito Y; Umemura S
Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
[TBL] [Abstract][Full Text] [Related]
9. Managing trastuzumab-resistant breast cancer.
Krop I
Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
[No Abstract] [Full Text] [Related]
10. Introduction. Herceptin: HER2 status--changing clinical practice.
Piccart M; Kaufmann M
Eur J Cancer; 2001 Jan; 37 Suppl 1():S1-2. PubMed ID: 11167084
[No Abstract] [Full Text] [Related]
11. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
12. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
Liao C; Yin F; Huang P; Cao Y; Gao F
Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
[No Abstract] [Full Text] [Related]
13. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
14. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
15. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
Roukos DH
J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
[No Abstract] [Full Text] [Related]
16. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
Heinzl S
Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
[No Abstract] [Full Text] [Related]
17. The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy.
Fox KF
Br J Cancer; 2006 Nov; 95(10):1454. PubMed ID: 17060943
[No Abstract] [Full Text] [Related]
18. HER-2-targeted therapy: lessons learned and future directions.
Nahta R; Esteva FJ
Clin Cancer Res; 2003 Nov; 9(14):5078-84. PubMed ID: 14613984
[TBL] [Abstract][Full Text] [Related]
19. Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
Araki K; Pegram M
Breast Cancer Res Treat; 2011 Jun; 127(2):589-90. PubMed ID: 19834800
[No Abstract] [Full Text] [Related]
20. Trastuzumab.
Perez EA; Palmieri FM; Brock SM
Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
[No Abstract] [Full Text] [Related]
[Next] [New Search]
